Conflict of interest statement: A.F. is a paid advisor and speaker for Ambry and Invitae. S.E.P. is on the scientific advisory board of Baylor Genetics. Theremaining authors declare no competing financial interests.176. Oxf Med Case Reports. 2018 Feb 9;2018(2):omx095. doi: 10.1093/omcr/omx095.eCollection 2018 Feb.An unexpected diagnosis in a patient with new-onset pulmonary infiltrates during adjuvant therapy for breast cancer.Aguiar-Bujanda D(1), Ros-Sanjuan L(1), Hernandez-Sosa M(1), Perera-Romero C(2).Author information: (1)Department of Medical Oncology, Hospital Universitario de Gran Canaria DrNegrin, c/ Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, Spain.(2)Department of Nuclear Medicine, Hospital Universitario de Gran Canaria DrNegrin, c/ Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, Spain.The differential diagnosis of new-onset pulmonary infiltrates during adjuvanttherapy in a cancer patient is challenging. Opportunistic infections, pulmonarydrug-induced toxicity and metastatic dissemination of the underlying cancer arethe most common causes. However, although infrequent, the development of a secondprimary pulmonary neoplasia should be taken into account. We present the clinicalcase of a breast cancer patient who developed progressive pulmonary infiltratesduring adjuvant therapy, who was finally diagnosed as having a second lungneoplasm of unexpected histology.DOI: 10.1093/omcr/omx095 PMCID: PMC5806405PMID: 29479451 